These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 19348592

  • 1. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P, Bernasconi E, Battegay M, Hirsch HH, Swiss HIV Cohort Study.
    Clin Infect Dis; 2009 May 15; 48(10):1459-66. PubMed ID: 19348592
    [Abstract] [Full Text] [Related]

  • 2. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC.
    Vaccine; 2004 May 07; 22(15-16):2006-12. PubMed ID: 15121313
    [Abstract] [Full Text] [Related]

  • 3. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.
    Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, Pedersen C, Mogensen CB, Nielsen L, Obel N.
    J Infect Dis; 2009 Jan 01; 199(1):77-83. PubMed ID: 19007313
    [Abstract] [Full Text] [Related]

  • 4. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 5. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Aug 01; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 7. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 8. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
    Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, Swiss HIV Cohort Study.
    AIDS; 2008 Jan 11; 22(2):301-6. PubMed ID: 18097233
    [Abstract] [Full Text] [Related]

  • 9. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
    Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N.
    Clin Infect Dis; 2008 Nov 15; 47(10):1345-53. PubMed ID: 18834317
    [Abstract] [Full Text] [Related]

  • 10. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Nov 15; 12(6):931-9. PubMed ID: 17926647
    [Abstract] [Full Text] [Related]

  • 11. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Nov 15; 12(6):889-97. PubMed ID: 17926643
    [Abstract] [Full Text] [Related]

  • 12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 13. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 14. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
    García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C.
    Am J Hematol; 2005 Dec 15; 80(4):271-81. PubMed ID: 16315252
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
    Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, Gerevini S, Bestetti A, Pedale R, Sala S, Sala S, Lazzarin A, Cinque P.
    Clin Infect Dis; 2005 Mar 01; 40(5):738-44. PubMed ID: 15714422
    [Abstract] [Full Text] [Related]

  • 16. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group.
    HIV Med; 2007 Mar 01; 8(2):96-104. PubMed ID: 17352766
    [Abstract] [Full Text] [Related]

  • 17. [Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].
    Ding YY, Jia WQ, Wang JS, Dong SL, Yang QH, Zhou RY, Qu SX, Lu LX, Wei J, Qiao XC, Gao MY, Guo XL, Zhang TJ, Wu ZY, He N.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec 01; 29(12):1176-80. PubMed ID: 19173958
    [Abstract] [Full Text] [Related]

  • 18. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.
    Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, Domingo P, Márquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Lacruz Rodrigo J, Mallolas J, de Miguel V, GESIDA 11/99 Study Group.
    Clin Infect Dis; 2003 Apr 15; 36(8):1047-52. PubMed ID: 12684918
    [Abstract] [Full Text] [Related]

  • 19. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy.
    Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, Dellamonica P, Botterel F, Dromer F, Chêne G.
    AIDS; 2006 Nov 14; 20(17):2183-91. PubMed ID: 17086058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.